Molecular Pathways

- Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and Limitations
  Jeyanthi Eswaran, Da-Qiang Li, Anil Shah, and Rakesh Kumar

Review

- Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
  Victor Moreno Garcia, Bristi Basu, L. Rhoda Molife, and Stan B. Kaye

HUMAN CANCER BIOLOGY

- Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact
  Mário Henrique M. Barros, Rocio Hassan, and Gerald Niedobitek

- Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-cell Leukemia/Lymphoma
  Yu Sawada, Motonobu Nakamura, Rieko Kabashima-Kubo, Takatoshi Shimauchi, Miwa Kobayashi, and Yoshiaki Tokura

- FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma
  Lisa E.S. Crose, Katherine T. Etheridge, Candy Chen, Brian Belyea, Lindsay J. Talbot, Rex C. Bentley, and Corinne M. Linardic

- Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia
  Jennifer R. Brown, Megan Hanna, Bethany Tesar, Lillian Werner, Nathalie Pochet, John M. Asara, Yaoyu E. Wang, Paolo dal Cin, Stacey M. Fernandes, Christina Thompson, Laura MacConaill, Catherine J. Wu, Yves Van de Peer, Mick Correll, Avi Regev, Donna Neuberg, and Arnold S. Freedman
Brachyury, a Driver of the Epithelial–Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer
Mario Roselli, Romaine I. Fernando, Fiorella Guadagni, Antonella Spilia, Jessica背景ristroni, Raffaele Palmiotto, Leonildo Costarelli, Mary Litzinger, Duane Hamilton, Bruce Huang, Joanne Tucker, Kwong-Yok Tsang, Jeffrey Schom, and Claudia Palena

Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression
Shu Feng, Longjiang Shao, Wendorng Yu, Paul Gavine, and Michael Ittmann

Resistance to TRAIL Is Mediated by DARPP-32 in Gastric Cancer
Abbes Belkhiri, Shoumin Zhu, Zheng Chen, Mohammed Souotto, and Wael El-Rifai

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belv, Lori S. Friedman, and Deepak Sampath

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice
Kinya Inoue, Takuji Torimura, Toru Nakamura, Hideki Iwamoto, Hiroshi Masuda, Mitsuhiko Abe, Osamu Hashimoto, Hiroshi Koga, Takato Ueno, Hirohisa Yano, and Michio Sata
### Imaging, Diagnosis, Prognosis

**3934**

**Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma**

Jordan Madic, Sophie Piperno-Neumann, Vincent Servois, Aurore Rampanou, Maud Milder, Bénédicte Trouiller, David Gentien, Stéphanie Saada, Franck Assayag, Aurélie Thuleau, Fariba Nennati, Didier Decaudin, François-Clément Bidard, Laurence Desjardins, Pascale Mariani, Olivier Lantz, and Marc-Henri Stern

---

**3942**

**A Replication Study and Genome-Wide Scan of Single-Nucleotide Polymorphisms Associated with Pancreatic Cancer Risk and Overall Survival**

Jason A. Willis, Sara H. Olson, Irene Orlow, Semanti Mukherjee, Robert R. McWilliams, Robert C. Kurtz, and Robert J. Klein

---

**3952**

**Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier**


### Predictive Biomarkers and Personalized Medicine

**3972**

**Predictive Value of XRCCI Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis**

Junjie Wu, Jie Liu, Yuhao Zhou, Jun Ying, Houdong Zou, Shicheng Guo, Lei Wang, Naqing Zhao, Jianjun Hu, Daru Lu, Li Jin, Qiang Li, and Jiu-Cun Wang

---

**3982**

**Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients**

Moubin Lin, Jian Gu, Cathy Eng, Lee M. Ellis, Michelle A. Hildebrandt, Jie Lin, Maosheng Huang, George A. Calin, Dingzhi Wang, Raymond N. Duflois, Ernest T. Hawk, and Xifeng Wu

---

**3992**

**Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy**

Yu-Yun Shao, Chien-Chung Huang, Shiou-Der Lin, Chih-Hung Hsu, and Ann-Lii Cheng

### Cancer Therapy: Clinical

**3961**

**Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients**


*See commentary p. 3719*

---

**3998**

**Correction: A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck**

The Journal of Clinical and Translational Research v www.aacrjournals.org

*Downloaded from clincancerres.aacrjournals.org on April 14, 2017. © 2012 American Association for Cancer Research.*
ABOUT THE COVER

The inhibition of androgen signaling is a major therapeutic strategy in prostate cancer; however, response is often transient, and patients ultimately relapse on therapy giving rise to a currently incurable condition known as castrate-resistant prostate cancer (CRPC). McCourt and colleagues show elevated expression of the androgen-regulated antiapoptotic protein c-FLIP in prostate cancer, which is further elevated in CRPC. Repression of c-FLIP induced apoptosis in non-castrate-resistant and CRPC cells and potentiated sensitivity to AR-targeted therapy, indicating that prostate cancer cells require c-FLIP to maintain viability. Consequently, targeting c-FLIP may represent a novel strategy to improve therapeutic response to the novel antiandrogen strategies under clinical development in CRPC. For details, see the article by McCourt and colleagues on page 3822 of this issue.